Compare DexCom, Inc. (DXCM) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Marvell Technology Inc — how do they compare? DexCom, Inc. trades at $84.08 (market cap $31.86B), while Marvell Technology Inc trades at $273.68 (market cap $246.84B). The key difference: Marvell Technology Inc is far larger — about 7.7× DexCom, Inc.'s market cap, and Marvell Technology Inc pays a 0.09% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Marvell Technology Inc for 42 Days on average.
| DXCM | MRVL | |
|---|---|---|
Market Cap | $31.86B | $246.84B |
Volume | 3,607,070 | 29,003,830 |
Sector | Health | Technology |
52-Week High | $92.34 | $316.43 |
52-Week Low | $54.84 | $73.73 |
Typical Hold Time | 62 Days | 42 Days |
Enterprise Value | $31.32B | $248.19B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Marvell Technology (MRVL) trades at $271.49, down 4.63% today but maintains strong momentum with 210% year-to-date gains. The stock shows bullish technical signals with support at $267 and resistance at $282. Fundamentally, MRVL reported three consecutive earnings beats and projects explosive growth, with fiscal 2028 revenue guidance raised to $18 billion. Analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $327.86 consensus target.
MRVL presents compelling growth prospects driven by AI chip demand and hyperscaler partnerships, particularly the $120 billion Google deal. However, elevated valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) warrant caution. The stock's 210% surge this year increases volatility risk, though strong institutional support and custom silicon expansion provide long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
